Skip to main content

Table 3 Clinical trials investigating the effect of CBD on subjective anxiety

From: Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research

Citation

Study design

Participants

Treatment(s)

Context

Treatment effect

Healthy participants

Zuardi et al. (1993) [207]

DB (PC); BSD

I: 10; 23 y

C: 10; 23 y

Oral 300 mg

Public speaking (90 min post-tx)

CBD sig. reduced SA post-public speaking. SA prior to, in anticipation of, and during speaking were unaffected.

Crippa et al. (2004) [45]

DB (PC); BSD

I: 5 M; 30 ± 5 y

C: 5 M; 30 ± 5 y

Oral 400 mg

Low stress

CBD sig. reduced SA 60 and 75 min post-tx.

Bhattacharyya et al. (2010) [18]

DB (PC); WSD

15 M; 27 ± 6 y

Oral 600 mg

Low stress

SA was unaffected 1, 2 and 3 h post-tx.

Martin-Santos et al. (2012) [123]

DB (PC); WSD

16 M; 26 ± 5 y

Oral 600 mg

Low stress

SA was unaffected 1, 2 and 3 h post-tx.

Hindocha et al. (2015) [86]

DB (PC); WSD

48; 22 y

Vaporised 16 mg

Low stress

SA was unaffected 2, 30, 60. 90 and 120 min post-tx.

Zuardi et al. (2017) [208]

DB (PC); BSD

I: 12 (6 M); 23 ± 3 y

I: 11 (5 M); 23 ± 3 y

I: 12 (6 M); 23 ± 3 y

C: 12 (6 M); 22 ± 2 y

I: Oral 100 mg

I: Oral 300 mg

I: Oral 900 mg

Public speaking

(150 min post-tx)

300 mg CBD sig. reduced SA compared to 900 mg CBD (but not placebo) during public speaking. SA prior to, in anticipation of, and post-speaking were not affected by any treatment.

Linares et al. (2019) [116]

DB (PC); BSD

I: 15 M; 24 ± 3 y

I: 15 M; 25 ± 3 y

I: 12 M; 23 ± 3 y

C: 15 M; 25 ± 4 y

I: Oral 150 mg

I: Oral 300 mg

I: Oral 600 mg

Public speaking

(90 min post-tx)

300 mg CBD (but not 150 or 600 mg) sig. reduced SA during public speaking. SA prior to, in anticipation of, and post-speaking were not affected by any treatment.

Clinical populations

Crippa et al. (2011) [44]

DB (PC); WSD

SAD Participants

10 M; 24 ± 4 y

Oral 400 mg

Low stress

CBD sig. reduced SA 60, 75 and 140 min post-Tx.

Bergamaschi et al. (2011) [15]

DB (PC); BSD

SAD Participants

I: 12 (6 M); 23 ± 2 y

C: 12 (6 M); 23 ± 2 y

Oral 600 mg

Public speaking

(90 min Post-Tx)

CBD sig. reduced SA during public speaking. SA prior to, in anticipation of, and post-speaking were not affected.

Hundal et al. (2017) [90]

DB (PC); BSD

High Trait Paranoia

I: 16 (8 M); 26 ± 9 y

C: 18 (8 M); 25 ± 8 y

Oral 600 mg

Virtual reality

(130 min Post-Tx)

SA was unaffected.

Masataka (2019) [124]

DB (PC); BSD

SAD Participants

I: 17 (8 M); 18–19 y

C: 20 (8 M); 18–19 y

Oral 300 mg·d-1 (28-days)

Low stress

CBD sig. reduced SA 4-weeks post-tx.

  1. BSD between-subject design, C control group, CBD cannabidiol, DB double-blind, I intervention group, M male subjects, PC placebo-controlled, SAD social anxiety disorder, SA subjective anxiety, SB single-blind, Tx treatment, WSD within-subject design
  2. The “Treatment effects” described are in comparison to a placebo condition, unless otherwise stated